Hepatitis Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL HEPATITIS DRUGS INDUSTRY

2.1 Summary about Hepatitis Drugs Industry

2.2 Hepatitis Drugs Market Trends

2.2.1 Hepatitis Drugs Production & Consumption Trends

2.2.2 Hepatitis Drugs Demand Structure Trends

2.3 Hepatitis Drugs Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Oral

4.2.2 Injection

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospitals

4.3.2 Clinics

4.3.3 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Oral

5.2.2 Injection

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospitals

5.3.2 Clinics

5.3.3 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Oral

6.2.2 Injection

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospitals

6.3.2 Clinics

6.3.3 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Oral

7.2.2 Injection

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospitals

7.3.2 Clinics

7.3.3 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Oral

8.2.2 Injection

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospitals

8.3.2 Clinics

8.3.3 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Oral

9.2.2 Injection

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospitals

9.3.2 Clinics

9.3.3 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 F. Hoffmann-La Roche

10.1.2 Gilead Sciences

10.1.3 GlaxoSmithKline

10.1.4 Johnson & Johnson

10.1.5 Merck

10.1.6 Novartis

10.1.7 Vertex Pharmaceuticals

10.1.8 Abbvie

10.1.9 Achillion Pharmaceuticals

10.1.10 Bristol-Myers Squibb

10.1.11 Dynavax Technologies

10.1.12 Mitsubishi Tanabe Pharma

10.2 Hepatitis Drugs Sales Date of Major Players (2017-2020e)

10.2.1 F. Hoffmann-La Roche

10.2.2 Gilead Sciences

10.2.3 GlaxoSmithKline

10.2.4 Johnson & Johnson

10.2.5 Merck

10.2.6 Novartis

10.2.7 Vertex Pharmaceuticals

10.2.8 Abbvie

10.2.9 Achillion Pharmaceuticals

10.2.10 Bristol-Myers Squibb

10.2.11 Dynavax Technologies

10.2.12 Mitsubishi Tanabe Pharma

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Hepatitis Drugs Product Type Overview

2.Table Hepatitis Drugs Product Type Market Share List

3.Table Hepatitis Drugs Product Type of Major Players

4.Table Brief Introduction of F. Hoffmann-La Roche

5.Table Brief Introduction of Gilead Sciences

6.Table Brief Introduction of GlaxoSmithKline

7.Table Brief Introduction of Johnson & Johnson

8.Table Brief Introduction of Merck

9.Table Brief Introduction of Novartis

10.Table Brief Introduction of Vertex Pharmaceuticals

11.Table Brief Introduction of Abbvie

12.Table Brief Introduction of Achillion Pharmaceuticals

13.Table Brief Introduction of Bristol-Myers Squibb

14.Table Brief Introduction of Dynavax Technologies

15.Table Brief Introduction of Mitsubishi Tanabe Pharma

16.Table Products & Services of F. Hoffmann-La Roche

17.Table Products & Services of Gilead Sciences

18.Table Products & Services of GlaxoSmithKline

19.Table Products & Services of Johnson & Johnson

20.Table Products & Services of Merck

21.Table Products & Services of Novartis

22.Table Products & Services of Vertex Pharmaceuticals

23.Table Products & Services of Abbvie

24.Table Products & Services of Achillion Pharmaceuticals

25.Table Products & Services of Bristol-Myers Squibb

26.Table Products & Services of Dynavax Technologies

27.Table Products & Services of Mitsubishi Tanabe Pharma

28.Table Market Distribution of Major Players

29.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

30.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

31.Table Global Hepatitis Drugs Market Forecast (Million USD) by Region 2021f-2026f

32.Table Global Hepatitis Drugs Market Forecast (Million USD) Share by Region 2021f-2026f

33.Table Global Hepatitis Drugs Market Forecast (Million USD) by Demand 2021f-2026f

34.Table Global Hepatitis Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f